What is GenrAb?
GenrAb operates at the intersection of immunology and neurology, focusing on the development of advanced neuroprotective therapies. By leveraging its proprietary Antibody Gene Signature technology, the company identifies and develops fully-human monoclonal antibodies designed to mitigate the progression of debilitating neurological conditions. Its lead therapeutic candidate, TGM-010, represents a cornerstone of this strategy, aiming to provide a transformative approach to patient care. Through this scientific rigor, GenrAb is establishing itself as a key player in the biotechnology sector, specifically targeting the unmet needs of patients suffering from complex neurodegenerative disorders.
How much funding has GenrAb raised?
GenrAb has raised a total of $5.6M across 1 funding round:
Angel/Seed
$5.6M
Angel/Seed (2025): $5.6M with participation from Actium Group
Key Investors in GenrAb
Actium Group
Actium Group is a strategic consulting firm that provides comprehensive guidance and project planning to high-growth enterprises, focusing on identifying operational gaps and driving long-term profitability.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GenrAb?
Following this major strategic investment, GenrAb is expected to prioritize the clinical advancement of TGM-010. The capital will likely be deployed to scale operational capabilities, expand research infrastructure, and facilitate the transition from preclinical validation to human clinical trials. As the company moves into this next phase of growth, the focus will remain on refining its antibody discovery platform and securing the necessary regulatory milestones to bring its neuroprotective solutions to market. This infusion of resources provides the necessary runway to solidify GenrAb's market position and enhance its long-term value proposition within the global healthcare ecosystem.
See full GenrAb company page
